Tagged with R

China Hong Chow, general manager of Roche Pharma China, shares Roche China’s incredible milestones over the past few years, including four pivotal oncology drugs listed on the National Reimbursement Drug List (NRDL) in 2017; the company’s USD 129 million investment in a new innovation center in Shanghai, the third strategic innovation…

Egypt Nadia Lamloum, executive director of the British Egyptian Business Association (BEBA), discusses the role of her institution and the investment opportunities that Egypt has to offer, as well as the initiatives being undertaken to form partnerships between industry, government officials and regulatory bodies.   Due to Egypt’s rising population, the demand…

Spain Javier Urzay, deputy director of Farmaindustria, gives an overview of the growth of the pharmaceutical sector in Spain and the challenges to find a balance between rewarding innovation and sustainability. Moreover, he talks about the development of clinical trials in Spain and the currently discussed new collaboration agreement with the…

France In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare policy under President Emmanuel Macron.   The integration of this entire sector completely resonates with our vision of a comprehensive…

Korea Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision to base his clinical trials in Australia and provides his assessment of the future for oncology drug development in the…

Rare Diseases Long regarded as a neglected backwater within the drug discovery landscape and the preserve of only a handful of niche players, the rare disease space has been undergoing an extraordinary turnaround in fortunes of late.   According to EvaluatePharma’s forecasts, orphan drug sales are set to grow 11 percent each…

Rare Diseases The 28th February 2019, marks the twelfth international Rare Disease Day. On and around this day hundreds of patient organisations from countries and regions across the globe will strive to raise awareness of some of the world’s rarest disease. For many of the rare diseases out there, we are yet to…

Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…

Opinion Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the US has been surprisingly slow in their adoption. Chip Davis, President and CEO, Association for Accessible Medicines breaks down the systematic challenges that must be addressed in order for the US biosimilars market to realize…

China The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines what he looks for in potential candidates for country manager positions in China.   What are the qualities you look…